Actionable news
0
All posts from Actionable news
Actionable news in HRTX: HERON THERAPEUTICS INC,

Heron Therapeutics Provides Update on FDA Review of SUSTOL® NDA

REDWOOD CITY, Calif.--(BUSINESS WIRE)--

Heron Therapeutics, Inc. (HRTX), announced today that the U.S. Food and Drug Administration (FDA) has provided the Company with an update on its review of the New Drug Application (NDA) for SUSTOL® (granisetron) Injection, extended release. The FDA has indicated that there are no substantive deficiencies in the NDA and has begun labeling discussions with the Company.

SUSTOL is a long-acting formulation of the FDA-approved 5-hydroxytryptamine type 3 (5-HT3) receptor antagonist granisetron being developed for the prevention of both acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC). SUSTOL is formulated utilizing Heron’s proprietary Biochronomer® drug...


More